VEC-DIC microscopy is critical as it allows real-time imaging of the movements of cellular structures smaller than the diffraction limit of light microscopy (~200 nm depending on the wavelength of light used) without labeling in live cells. Objects as small as individual microtubules (25 nm) can be detected, and 50 nm–80 nm diameter vesicles can be visualized moving on a single microtubule. In the isolated axoplasm, the density of microtubules, neurofilaments, and vesicular structures is too great to resolve and track individual particles. Nonetheless, the trafficking of vesicles in both directions can be visualized and average speeds measured interactively in real time.
The isolated axoplasm perfusion model uses axonal transport as a reporter of specific disease-relevant cellular functions and can be used to define specific targets and mechanisms. The isolated axoplasm model in combination with VEC-DIC microscopy avoids many of the limitations of transfection and injection methods, as it provides unparalleled control of experimental conditions, including concentration of mutant proteins, buffer conditions, and cell physiology. Unlike transfection or injection paradigms, the axoplasm perfusion model introduces a protein at concentrations comparable to physiological levels uniformly throughout the axoplasm. Transfected proteins cannot be expressed at a defined concentration and maintained at a specific concentration, particularly in axonal domains that can be quite distant from sites of synthesis. Newly synthesized proteins must be assembled into complexes that are transported to the axon. Injections are present as a bolus that will be at a high local concentration and then must redistribute either by diffusion or transport, also making it difficult to estimate effective concentrations and specific actions. Studies using lysates are further limited by disruption of normal compartmentation and dilution by orders of magnitude in non-physiological buffers. Transfection, injection, and in vitro lysates are indirect as they do not provide a simple biological readout or identify a unique axonal target, such as the pathogenic cytoplasmic proteins in ALS.
The reproducibility of these transport assays allows us to see the acute effects of pharmacological inhibitors, enzymes, and pathological proteins. As a result, axoplasm has proven to be a powerful tool in dissecting pathogenic mechanisms of mutant and modified proteins. For example, more than 40 different proteins have been shown to cause familial forms of amyotrophic lateral sclerosis (ALS). These proteins (including SOD127, Fus29, profilin, and TDP43) are not obviously related in function or sequence. Further, many of the proteins produced by these mutant genes are widely expressed in both neuronal and non-neuronal tissues, yet the mutant forms of these proteins selectively affect upper and lower motor neurons.
Using the axoplasm model, it was demonstrated that pathological forms of multiple different familial ALS proteins preferentially inhibit kinesin-based fast axonal transport. This was first documented using multiple different mutants of SOD114,27, showing that they all activated P38 MAP Kinase, which phosphorylated kinesin and inhibited transport. Subsequent experiments showed that this effect was not due to a direct action of SOD1 on P38 MAP kinase but instead was mediated through interactions with the MAP kinase kinase kinase ASK115 as part of a MAP kinase signaling pathway. The same pathway was activated by mutant Fus29 and has now been demonstrated with profilin, TDP43, and one of the dipeptides produced by mutant C9ORF7230. The importance of this pathway in familial and sporadic forms of ALS has subsequently been confirmed in mouse models, IPSC-derived models, and in human patient postmortem tissue14,15,29,30.
The axoplasm model has several key advantages. For example, the lack of a plasma membrane permits precise control over the concentration of perfused elements, either singly or in combination. The experimental conditions are near native with respect to the organization of axoplasmic structures and buffer conditions. Effects are measured interactively in real time. Pathological and physiological effects that are unique to the axon can be evaluated without the confound of cell body effects and protein synthesis. Similarly, axonal events are separated from synaptic actions30. Some of these advantages also impose limitations on experiments. The axoplasm model allows analysis of a single subcellular compartment, separating cell body and axonal events. As a result, one cannot tag vesicles containing specific cargoes. Effects of experimental manipulations are limited to the axon, and there may be different effects on the cell body or synapse-specific processes30. Similarly, the absence of a plasma membrane means that membrane-based activities cannot be evaluated, although downstream signaling pathways can be assessed. However, most proteins implicated in adult-onset neurodegeneration are cytoplasmic proteins that can be evaluated in the axoplasm. There are many experiments that can only be done in the isolated axoplasm model, but results obtained with the axoplasm facilitate the design of studies in intact neurons and organisms by generating information on mechanisms that can be tested in other models.
In recent years, some have argued that human diseases are unique and can only be studied in humans and human tissues/cells. However, over a hundred years of research on adult-onset neurodegenerative diseases like ALS has not yielded effective therapies or even a consistent pathogenic mechanism to explain the disease. The complexity of humans and the limited types of experimental approaches feasible with human samples have frustrated many outstanding scientists. Use of well-designed model systems, such as the one provided by the isolated axoplasm preparation, can answer specific questions related to disease pathology and provide insights that can then be validated in human tissue and potentially translated into therapies. The key is to ask the right questions and interpret the data using complementary model systems.